On June 8, 2011, the FDA announced safety label changes for the cholesterol-lowering medication simvastatin because the highest approved dose of 80 mg has been associated with an elevated risk of myopathy (muscle injury), particularly during the first 12 months of use. There are also new contraindications and/or dose limitations of simvastatin when used with certain medications. Click here for more information.

Recent Plan News